About SOPHiA GENETICS
SOPHiA GENETICS is a health technology company that has built SOPHiA DDM™, an AI-powered platform for precision medicine that transforms complex health data into actionable clinical insights. The platform serves healthcare providers, biopharma companies, and patients globally, focusing primarily on oncology and rare genetic disorders. With a network of over 990 healthcare institutions across 75+ countries, SOPHiA GENETICS has analyzed more than 2.5 million genomic profiles. The company's technology combines advanced AI analytics with cloud-based infrastructure to deliver 98-99% accuracy across multiple health data sets. Their platform supports comprehensive genomic analysis including solid tumors, blood cancers, hereditary cancers, liquid biopsy, and rare and inherited disorders. SOPHiA GENETICS offers end-to-end solutions from library preparation through variant interpretation, with applications spanning clinical exomes, whole exomes, and targeted panels. The company emphasizes data sovereignty, ensuring healthcare institutions maintain full control of their data while benefiting from collective intelligence across the global network. Their diverse team from 28 countries includes 30% PhD holders, bringing deep expertise in biology, data science, and clinical genomics. SOPHiA GENETICS is committed to breaking barriers in healthcare access, working to ensure every patient has access to precision care regardless of location or circumstance.
Mission & Story
Mission
Democratizing data-driven medicine, together. We believe in the philosophy of using 'data for good.' Our aim is to create a world where every cancer or rare genetic disease patient has equal access to precision care.
Clinical Focus
Medical conditions and clinical areas addressed by SOPHiA GENETICS.
Who It Serves
Milestones & Awards
Recent Milestones
Reached 2 million genomic profiles analyzed milestone; announced Master Collaboration Agreement with ARC Regulatory for IVDR expertise; launched Enhanced Exome Solutions; expanded liquid biopsy capabilities with MSK-ACCESS; partnership with Jessa Ziekenhuis announced at European Congress of Pathology
Key Partnerships
Social & Media
Latest Updates
Diversity in Genomic Analysis: An example of how SOPHiA GENETICS has built more accurate health data analysis for diverse populations
Celebrating 1 Year of SOPHiA DDM™ Homologous Recombination Deficiency (HRD) Solution!
Celebrating Clinical Trials Day
In the Face of Rare Disease: The Inspiring Story of Brooklynn
The Launch of SOPHiA DDM™ Dispatch
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.